WHWK Whitehawk Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1422142 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-72.5%
TTM net income YoY67.7%
TTM EPS YoY86.0%
Revenue 3-yr CAGR-22.3%
Net income 3-yr CAGR—
Margins
Gross margin89.4%
Operating margin-1,601.1%
Net margin-288.3%
FCF margin-1,371.4%
EBITDA margin-1,600.0%
Returns
ROE-21.8%
ROA-18.6%
ROIC (approx.)-147.5%
Asset turnover0.06x
Leverage & solvency
Liabilities / assets9.6%
Debt / equity0.00x
Current ratio10.26x
Interest coverage—
Cash quality & payout
Operating cash flow / net income4.73x
Accruals ratio69.5%
Payout ratio—
Capex / revenue7.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $7.14M | $7.24M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $760,000 | $790,000 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $6.38M | $6.45M |
| R&D expense | $18.14M | $12.89M | $17.23M | $19.02M | $14.35M | $48.81M | $8.79M | $14.35M |
| SG&A expense | $4.80M | $5.22M | $6.29M | $5.87M | $5.20M | $5.94M | $12.81M | $11.05M |
| Operating income | -$22.94M | -$18.11M | -$23.52M | -$24.89M | -$19.55M | -$54.75M | -$15.22M | -$18.95M |
| Interest expense | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Pretax income | -$21.21M | -$16.64M | -$22.19M | -$23.25M | -$17.75M | -$52.62M | $73.02M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$21.21M | -$16.64M | -$22.19M | -$23.25M | -$17.75M | -$52.62M | $73.02M | -$18.27M |
| EBITDA | -$22.94M | -$18.11M | -$23.52M | -$24.89M | -$19.54M | -$54.73M | -$15.16M | -$18.90M |
| EPS (basic) | -0.23 | -0.20 | -0.32 | — | -0.26 | -0.76 | 1.84 | — |
| EPS (diluted) | -0.23 | -0.20 | -0.32 | — | -0.26 | -0.76 | 1.83 | — |
| Weighted avg. shares (diluted) | 93.87M | 82.89M | 69.24M | — | 69.20M | 69.08M | 39.93M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $68.97M | $85.23M | $34.79M | $37.57M | $37.93M | $144.94M | $227.57M | $28.67M |
| Short-term investments | $100.70M | $104.75M | $88.25M | $108.13M | $124.67M | $32.26M | $3.49M | $18.57M |
| Receivables | — | — | — | $0 | $0 | $0 | $0 | $5.90M |
| Inventory | — | — | — | $0 | $0 | $0 | $0 | $5.31M |
| Current assets | $171.97M | $192.41M | $125.55M | $149.01M | $165.04M | $178.67M | $232.61M | $61.29M |
| PP&E, net | $3,000 | $1,000 | $2,000 | $3,000 | $4,000 | $9,000 | $25,000 | $6.85M |
| Total assets | $173.69M | $193.99M | $127.23M | $150.83M | $167.02M | $180.82M | $234.00M | $70.32M |
| Current liabilities | $10.44M | $11.07M | $11.06M | $14.52M | $9.85M | $8.76M | $12.27M | $17.07M |
| Total liabilities | $10.53M | $11.07M | $11.06M | $14.52M | $9.85M | $8.76M | $12.27M | $17.84M |
| Shareholders' equity | $163.16M | $182.93M | $116.17M | $136.31M | $157.17M | $172.07M | $221.73M | $52.48M |
| Shares outstanding | 59.01M | 57.01M | 47.20M | 47.15M | 47.13M | 47.13M | 46.78M | 24.68M |
| Cash flow statement | ||||||||
| Operating cash flow | -$19.67M | -$14.53M | -$22.21M | -$17.23M | -$15.38M | -$52.96M | -$11.86M | -$15.05M |
| Capital expenditure | $3,000 | $0 | $0 | $0 | $0 | $1,000 | $551,000 | $186,000 |
| Free cash flow | -$19.68M | -$14.53M | -$22.21M | -$17.23M | -$15.38M | -$52.96M | -$12.41M | -$15.24M |
| Investing cash flow | $3.61M | -$16.87M | $19.43M | $16.85M | -$91.63M | -$28.83M | $115.50M | $13.13M |
| Financing cash flow | -$194,000 | $81.84M | $0 | $25,000 | $0 | -$850,000 | $95.20M | $53,000 |
| Depreciation & amortization | $800 | $1,000 | $1,000 | $1,000 | $5,600 | $15,300 | $57,000 | $47,000 |
| Stock-based compensation | $1.75M | $1.52M | $2.19M | $2.39M | $2.72M | $3.09M | $1.68M | $1.85M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.